Chronic treatment with novel gpr40 agonists improve whole- Body glucose metabolism based on the glucose-dependent insulin secretion

Journal of Pharmacology and Experimental Therapeutics

Volumn 346, Issue 3, 2013, Pages 443-452

  Tanaka, Hirotsugu ^a   Yoshida, Shigeru ^a   Oshima, Hiroyuki ^a   Minoura, Hideaki ^a   Negoro, Kenji ^a   Yamazaki, Takao ^a   Sakuda, Shuichi ^a   Iwasaki, Fumiyoshi ^a   Matsui, Tetsuo ^a   Shibasaki, Masayuki ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 FLUORO 4 [[[1 (2 PHENOXYETHYL) 1,2,3,4 TETRAHYDROQUINOLIN 5 YL]METHYL]AMINO]PHENYL]PROPANOATE MAGNESIUM; ANTIDIABETIC AGENT; AS 1975063; AS 2031477; AS 2034178; BIS[2 [[4 [[4' (HYDROXYETHOXY) 2' METHYL[1,1' BIPHENYL] 3 YL]METHOXY]PHENYL]METHYL] 3,5 DIOXO 1,2,4 OXADIAZOLIDIN 4 IDE]TETRAHYDRATE; G PROTEIN COUPLED RECEPTOR 40; GLUCOSE; HEMOGLOBIN A1C; LINOLEIC ACID; METFORMIN; PIOGLITAZONE; SODIUM 2 [[4 [(2',6' DIMETHYL[1,1' BIPHENYL] 3 YL)METHOXY]PHENYL]METHYL] 3,5 DIOXO 1,2,4 OXADIAZOLIDIN 4 IDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG ABSORPTION; DRUG HALF LIFE; DRUG MECHANISM; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; SINGLE DRUG DOSE;

ANIMALS; BIPHENYL COMPOUNDS; BLOOD GLUCOSE; CALCIUM; CHO CELLS; CRICETINAE; CRICETULUS; DIABETES MELLITUS; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; INSULIN; MALE; MICE; MICE, INBRED ICR; MICE, OBESE; OXADIAZOLES; PPAR GAMMA; RATS; RATS, ZUCKER; RECEPTORS, G-PROTEIN-COUPLED; TRANSCRIPTIONAL ACTIVATION;

EID: 84882313066     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.206466     Document Type: Article

References (31)

1. U K Prospective Diabetes Study Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865.
2. Araki T, Hirayama M, Hiroi S, and Kaku K (2012) GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes. Diabetes Obes Metab 14:271-278.
3. Bode B (2011) Liraglutide: a review of the first once-daily GLP-1 receptor agonist. Am J Manag Care 17 (Suppl. 2)S59-S70.
4. Briscoe CP, Tadayyon M, Andrews JL, Benson WG, Chambers JK, Eilert MM, Ellis C, Elshourbagy NA, Goetz AS, and Minnick DT, et al. (2003) The orphan G proteincoupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem 278:11303-11311.
5. Burant CF, Viswanathan P, Marcinak J, Cao C, Vakilynejad M, Xie B, and Leifke E (2012) TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 379:1403-1411.
6. Campbell RK, White JR, Jr, and Saulie BA (1996) Metformin: a new oral biguanide. Clin Ther 18:360-371, discussion 359.
7. Charbonnel B, Steinberg H, Eymard E, Xu L, Thakkar P, Prabhu V, Davies MJ, and Engel SS (2013) Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy wi th liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial. Diabetologia 56:1503-1511 Epub ahead of print.
8. Christiansen E, Urban C, Merten N, Liebscher K, Karlsen KK, Hamacher A, Spinrath A, Bond AD, Drewke C, and Ullrich S, et al. (2008) Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA(1)/GPR40), a potential target for the t reatment of type II diabetes. J Med Chem 51:7061-7064.
9. Engel SS, Williams-Herman DE, Golm GT, Clay RJ, Machotka SV, Kaufman KD, andGoldstein BJ (2010) Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract 64:984-990.
10. Fujiwara K, Maekawa F, and Yada T (2005) Oleic acid inter acts with GPR40 to induce Ca21 signaling in rat islet beta-cells: mediation by PLC and L-type Ca21 channel and link to insulin release. Am J Physiol Endocrinol Metab 289: E670-E677.
11. Hanefeld M, Patwardhan R, and Jones NP; Rosiglitazone Clinical Trials Study Group (2007) A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes. Nutr Metab Cardiovasc Dis 17: 13-23.
12. Hauner H (2002) The mode of action of thiazolidinediones. Diabetes Metab Res Rev 18 (Suppl 2):S10-S15.
13. Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, and Keymeulen B, et al. (2006) Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 91:4612-4619.
14. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, and Landau BR, et al. (2000) Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 49:2063-2069.
15. Ikeda H, Taketomi S, Sugiyama Y, Shimura Y, Sohda T, Meguro K, and Fujita T (1990) Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneimittelforschung 40:156-162.
16. Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, Fukusumi S, Ogi K, Hosoya M, Tanaka Y, and Uejima H, et al. (2003) Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 422:173-176.
17. Klip A and Leiter LA (1990) Cellular mec hanism of action of metformin. Diabetes Care 13:696-704.
18. Lin DC, Zhang J, Zhuang R, Li F, Nguyen K, Chen M, Tran T, Lopez E, Lu JY, and Li XN, et al. (2011) AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents. PLoS ONE 6:e27270.
19. Melander A, Lebovitz HE, and Faber OK (1990) Sulfonylureas. Why, which, and how? Diabetes Care 13 (Suppl 3):18-25.
20. Minoura H, Takeshita S, Ita M, Hirosumi J, Mabuchi M, Kawamura I, Nakajima S, Nakayama O, Kayakiri H, and Oku T, et al. (2004) Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614. Eur J Pharmacol 494: 273-281.
21. Minoura H, Takeshita S, Yamamoto T, Mabuchi M, Hirosumi J, Takakura S, Kawamura I, Seki J, Manda T, and Ita M, et al. (2005) Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat. Eur J Pharmacol 519: 182-190.
22. Nagasumi K, Esaki R, Iwachidow K, Yasuhara Y, Ogi K, Tanaka H, Nakata M, Yano T, Shimakawa K, and Taketomi S, et al. (2009) Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insuli n secretion and improves glucose tolerance in normal and diabetic mice. Diabetes 58:1067-1076.
23. Pfeifer MA, Halter JB, Judzewitsch RG, Beard JC, Best JD, Ward WK, and Porte D, Jr. (1984) Acute and chronic effects of sulfonylurea drugs on pancreatic islet function in man. Diabetes Care 7 (Suppl 1):25-34.
24. Prentki M, Tornheim K, and Corkey BE (1997) Signal transduction mechanisms in nutrient-induced insulin secretion. Diabetologia 40 (Suppl 2):S32-S41.
25. Sakamoto Y, Oyama J, Ikeda H, Kuroki S, Gondo S, Iwamoto T, Uchida Y, Kodama K, Hiwatashi A, and Shimomura M, et al.; S-DOG investigators (2013) Effects of sitagliptin beyond glycemic control: focus on quality of life. Cardiovasc Diabetol 12: 35 DOI: 10.1186/1475-2840-12-35
26. Smith U (2001) Pioglitazone: mechanism of action. Int J Clin Pract Suppl :13-18.
27. Steele R (1959) Influences of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci 82:420-430.
28. Tan CP, Feng Y, Zhou YP, Eiermann GJ, Petrov A, Zhou C, Lin S, Salituro G, Meinke P, and Mosley R, et al. (2008) Selective small-molecule agonists of G proteincoupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Diabetes 57:2211-2219.
29. Taylor SJ, Chae HZ, Rhee SG, and Exton JH (1991) Activation of the beta 1 isozyme of phospholipase C by alpha subunits of the Gq class of G proteins. Nature 350: 516-518.
30. Tsujihata Y, Ito R, Suzuki M, Harada A, Negoro N, Yasuma T, Momose Y, and Takeuchi K (2011) TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. J Pharmacol Exp Ther 339:228-237.
31. Wang JS, Lin SD, Lee WJ, Su SL, Lee IT, Tu ST, Tseng YH, Lin SY, and Sheu WH (2011) Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24- week, randomized, open-label, parallel-group comparison. Clin Ther 33:1932-1942.